Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jesus A. Araujo, M.D., Ph.D.
Jesus A. Araujo, M.D., Ph.D.

Specialty:

Internal Medicine
Cardiology

General Information:

Gender:
Male
Language(s):
English, Spanish

Affiliation(s):

Assistant Professor of Medicine, Department of Medicine, Cardiology
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Cardiovascular Disease, UCLA School of Medicine, 1998 - 2003
Residency:
Internal Medicine, Beth Israel Medical Center, 1995 - 1998
Internship:
Internal Medicine, Beth Israel Medical Center, 1994 - 1995
Medical Degree:
M.D., Universidad Central de Venezuela, 1991
Degree:
Ph.D., Molecular Biology, Molecular Biology Institute, UCLA, 2004

Certification(s):

Board Certification(s):
Echocardiography, National Board of Echocardiography, 2004
Internal Medicine, American Board of Internal Medicine, 1997

Contact Information:

Phone:
(310) 825-3222
Email:
Website:

Practice Information:

Clinical Interest(s):
General cardiology
Echocardiography

Scientific Interest(s):

Dr. Jesus Araujo's research interests are focused on dissecting mechanisms, molecular pathways and gene-environment interactions of relevance in the induction of cardiopulmonary effects by air pollutants. His Environmental Cardiology and Vascular Biology Laboratory is studying how air particulate matter (PM) promotes atherosclerosis and ischemic heart disease, likely via the promotion of systemic prooxidative and proinflammatory effects that may occur as a consequence of similar effects in the Lungs. Dr. Araujo is also interested to determine how PM-induced pro-oxidative and pro-inflammatory effects in the lungs may lead to DNA damage and pro-oncogenic effects, which appear to be similar to effects caused by passive cigarette smoking.

Selected Cancer-Related Publications:

Hickey MJ, Malone CC, Erickson KE, Gomez GG, Young EL, Liau LM, Prins RM, Kruse CA. Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. Am J Transl Res. 2012;4(1):114-26. Epub 2012 Jan 10.

Ma W, Chen M, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse CA, Grotjahn D, Ichim T, Minev B. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Intl. J. Nanomed. 2012 7, 1475-1487.

Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010 Oct 14;8:100.

Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA.Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010 Oct 14;8:100.

Gomez GG, Hickey MJ, Tritz R, Kruse CA. Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors. Gene Ther Mol Biol. 2008 Jun;12(1):101-110.